The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET.
Journal
Nature reviews. Rheumatology
ISSN: 1759-4804
Titre abrégé: Nat Rev Rheumatol
Pays: United States
ID NLM: 101500080
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
accepted:
08
12
2020
pubmed:
8
1
2021
medline:
10
3
2021
entrez:
7
1
2021
Statut:
ppublish
Résumé
During the COVID-19 pandemic, the need to provide high-level care for a large number of patients with COVID-19 has affected resourcing for, and limited the routine care of, all other conditions. The impact of this health emergency is particularly relevant in the rare connective tissue diseases (rCTDs) communities, as discussed in this Perspective article by the multi-stakeholder European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET). The clinical, organizational and health economic challenges faced by health-care providers, institutions, patients and their families during the SARS-CoV-2 outbreak have demonstrated the importance of ensuring continuity of care in the management of rCTDs, including adequate diagnostics and monitoring protocols, and highlighted the need for a structured emergency strategy. The vulnerability of patients with rCTDs needs to be taken into account when planning future health policies, in preparation for not only the post-COVID era, but also any possible new health emergencies.
Identifiants
pubmed: 33408338
doi: 10.1038/s41584-020-00565-z
pii: 10.1038/s41584-020-00565-z
pmc: PMC7786339
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
177-184Commentaires et corrections
Type : ErratumIn
Références
World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/ (2020).
Rare Barometer. How has COVID-19 impacted people with rare diseases? https://download2.eurordis.org/rbv/covid19survey/covid_infographics_final.pdf (2020).
McInnes, I. B. COVID-19 and rheumatology: first steps towards a different future? Ann. Rheum. Dis. 79, 551–552 (2020).
doi: 10.1136/annrheumdis-2020-217494
Richez, C., Lazaro, E., Lemoine, M., Truchetet, M. E. & Schaeverbeke, T. Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases. Joint Bone Spine 87, 187–189 (2020).
doi: 10.1016/j.jbspin.2020.03.010
Felten, R., Chatelus, E. & Arnaud, L. How and why are rheumatologists relevant to COVID-19? Joint Bone Spine https://doi.org/10.1016/j.jbspin.2020.04.006 (2020).
doi: 10.1016/j.jbspin.2020.04.006
pubmed: 32451147
pmcid: 7191283
Mahévas, M. et al. Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 369, m1844 (2020).
doi: 10.1136/bmj.m1844
Ferro, F. et al. COVID-19: the new challenge for rheumatologists. Clin. Exp. Rheumatol. 38, 17–80 (2020).
doi: 10.55563/clinexprheumatol/r3k9l6
Ferro, F. COVID-19: the new challenge for rheumatologists. First update. Clin. Exp. Rheumatol. 38, 373–382 (2020).
doi: 10.55563/clinexprheumatol/r3k9l6
Yazdany, J. & Kim, A. H. J. Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. Ann. Intern. Med. 172, 754–755 (2020).
doi: 10.7326/M20-1334
Dejaco, C. et al. Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2020-218697 (2020).
doi: 10.1136/annrheumdis-2020-218697
pubmed: 33158877
Ziadé, N. et al. The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study. Clin. Rheumatol. 39, 3205–3213 (2020).
doi: 10.1007/s10067-020-05428-2
Misra, D. P., Agarwal, V., Gasparyan, A. Y. & Zimba, O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin. Rheumatol. 39, 2055–2062 (2020).
doi: 10.1007/s10067-020-05073-9
Monti, S. et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann. Rheum. Dis. 79, 667–668 (2020).
doi: 10.1136/annrheumdis-2020-217424
Yen, E., Singh, D. R. & Singh, R. R. 48-year trends in systemic sclerosis mortality, 1968–2015: a United States population-based study. Arthritis Care Res. https://doi.org/10.1002/acr.24411 (2020).
doi: 10.1002/acr.24411
Ogata, Y. et al. Morbidity and mortality in antiphospholipid syndrome based on cluster analysis: a 10-year longitudinal cohort study. Rheumatology https://doi.org/10.1093/rheumatology/keaa542 (2020).
doi: 10.1093/rheumatology/keaa542
Chen M., Wei Y., Zhang Q., Wan Q., Chen X. Epidemiology and clinical characteristics of COVID-19 in rheumatic diseases at a tertiary care hospital in Wuhan, China. Clin. Exp. Rheumatol. https://www.clinexprheumatol.org/article.asp?a=15961 (2020).
Mason, A., Rose, E. & Edwards, C. J. Clinical management of lupus patients during the COVID-19 pandemic. Lupus 29, 1661–1672 (2020).
doi: 10.1177/0961203320961848
Minniti, A. et al. Taking care of systemic sclerosis patients during COVID-19 pandemic: rethink the clinical activity. Clin. Rheumatol. 39, 2063–2065 (2020).
doi: 10.1007/s10067-020-05191-4
Robinson, P. C. & Yazdany, J. The COVID-19 global rheumatology alliance: collecting data in a pandemic. Nat. Rev. Rheumatol. 16, 293–294 (2020).
doi: 10.1038/s41584-020-0418-0
Società Italiana di Reumatologia. Registro COVID-19-RMD SIR. https://redcap.reumatologia.it/surveys/?s=YLDERDE88W (2020).
Gianfrancesco, M. A. et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2, e250–e253 (2020).
doi: 10.1016/S2665-9913(20)30095-3
Gianfrancesco, M. et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 79, 859–866 (2020).
doi: 10.1136/annrheumdis-2020-217871
Haşlak, F., Yıldız, M., Adrovic, A., Barut, K. & Kasapçopur, Ö. Childhood rheumatic diseases and COVID-19 pandemic: an intriguing linkage and a new horizon. Balkan Med. J. 37, 184–188 (2020).
pubmed: 32264666
pmcid: 7285673
Landewé, R. B. et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann. Rheum. Dis. 79, 851–858 (2020).
doi: 10.1136/annrheumdis-2020-217877
Matucci-Cerinic, M. et al. Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Ann. Rheum. Dis. 79, 724–726 (2020).
doi: 10.1136/annrheumdis-2020-217407
Bozzalla Cassione, E. et al. COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann. Rheum. Dis. 79, 1382–1383 (2020).
doi: 10.1136/annrheumdis-2020-217717
Cavagna, L. et al. Telemedicine in rheumatology: a reliable approach beyond the pandemic. Rheumatology https://doi.org/10.1093/rheumatology/keaa554 (2020).
doi: 10.1093/rheumatology/keaa554
pubmed: 32681167
pmcid: 8487649
Romão, V. C. et al. Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view. RMD Open 6, e001314 (2020).
doi: 10.1136/rmdopen-2020-001314
Wuyts, W. A., Cottin, V., Spagnolo, P. & Wells, A. U. (Eds) Pulmonary Manifestations of Systemic Diseases. (European Respiratory Society, 2019).
Takla, M. & Jeevaratnam, K. Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety. Saudi Pharm. J. https://doi.org/10.1016/j.jsps.2020.11.003 (2020).
doi: 10.1016/j.jsps.2020.11.003
pubmed: 33204210
pmcid: 7662033
Lupus Europe. Hydroxychloroquine: patient reported availability. A survey amongst lupus patients. https://www.lupus-europe.org/wp-content/uploads/2020/04/survey-Hcq-Learning-0410-Fin.pdf (2020).
World Health Organisation. COVID-19: Operational guidance for maintaining essential health services during an outbreak Interim guidance, 25 March 2020. https://apps.who.int/iris/bitstream/handle/10665/331561/WHO-2019-nCoV-essential_health_services-2020.1-eng.pdf?sequence=1&isAllowed=y (2020).
Mazzoleni, S., Turchetti, G. & Ambrosino, N. The COVID-19 outbreak: from “black swan” to global challenges and opportunities. Pulmonology 26, 117–118 (2020).
doi: 10.1016/j.pulmoe.2020.03.002
European Commission. The common EU response to COVID-19. https://europa.eu/european-union/coronavirus-response_en#eu-actions (2020).
European Commission. ERNs and COVID-19. https://ec.europa.eu/health/ern/covid-19_en (2020).
European Commission. What are the ERNs doing to help patients affected by rare diseases and COVID-19? https://ec.europa.eu/health/sites/health/files/ern/docs/covid19_erns_en.pdf (2020).
ERN ReCONNET. Update on COVID-19 outbreak. https://reconnet.ern-net.eu/update-on-covid-19-outbreak/ (2020).
Fai2R. The news. https://www.fai2r.org/actualites/covid-19 (2020).
ERN ReCONNE. COVID-19: ERN ReCONNET endorsed recommendations. https://reconnet.ern-net.eu/covid-19-ERN%20ReCONNET/ (2020).
Cutolo, M., Smith, V. & Paolino, S. Understanding immune effects of oestrogens to explain the reduced morbidity and mortality in female versus male COVID-19 patients. Comparisons with autoimmunity and vaccination. Clin. Exp. Rheumatol. 38, 383–386 (2020).
pubmed: 32452350
Garazzino, S. et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Eurosurveillance 25, 2000600 (2020).
doi: 10.2807/1560-7917.ES.2020.25.18.2000600
Rivieccio, B. A. et al. Heterogeneity of COVID-19 outbreak in Italy. Acta Biomed. 91, 31–34 (2020).
pubmed: 32420921
pmcid: 7569642
Istituto Superiore di Sanità. Special section on COVID-19. https://www.iss.it/coronavirus (2020).
Istituto Superiore di Sanità. Rapporti ISS COVID-19 in English. https://www.iss.it/rapporti-iss-covid-19-in-english (2020).